The reduction in cerebrospinal fluid and plasma p-tau by the recently approved anti-amyloid monoclonal antibodies in clinical trials support a downstream effect of amyloid-reducing agents on AD tau pathology as well [71]. This evidence concerns the gene MAPT and amyloidosis.